Pure Monograph vs IQVIA
IQVIA is one of the largest contract research organizations in the world. Pure Monograph is a self-serve AI authoring platform. The two sit in different categories and solve different problems; direct head-to-head comparison misses the point.
Short answer. IQVIA is an enterprise CRO and data provider. Pure Monograph is an AI platform for regulatory and CMC authoring and intelligence. They overlap only at the edges — most sponsors who use Pure Monograph either have no CRO yet or are already retaining IQVIA for trial operations while running regulatory drafting internally.
At a glance
| Dimension | Pure Monograph | IQVIA |
|---|---|---|
| Primary deliverable | AI-authored CTD sections, tech transfer packages, BMRs, intelligence briefs | Full-service clinical trials, real-world evidence, commercial analytics |
| Category | SaaS platform + concierge packages | Publicly traded CRO (NYSE: IQV) |
| Regulatory output | Module 3 drafts, ICH Q-series alignment, stability and comparability content | Full regulatory submissions via consulting engagement |
| Pricing | $0-$1,499 per month self-serve; $7,500-$80,000 USD per request-based package | Enterprise contracts (typical CRO engagements start at six figures and scale up) |
| Engagement model | Self-serve subscription plus optional concierge package | Consulting engagement with dedicated project teams |
| Ownership | Burrard Pharmaceutical Enterprises Ltd., Vancouver BC | IQVIA Holdings Inc., Durham NC, USA (NYSE: IQV) |
Where each wins
IQVIA is the right tool when you are outsourcing an actual trial program, buying longitudinal patient-level data, or running commercial strategy at global scale. The price reflects that scope.
Pure Monograph is the right tool when your regulatory and CMC team wants AI drafting support without signing a CRO engagement. The platform handles CTD Module 3 Q&A, Tech Transfer package assembly, BMR authoring per 21 CFR 211.188, and stability design per ICH Q1A(R2) — work that does not require a full CRO footprint.
Using both together
Common pattern: sponsor retains IQVIA for clinical trial operations and pharmacovigilance. Internal regulatory and CMC teams use Pure Monograph to draft Module 3, tech transfer, and manufacturing documentation without escalating every draft to an external consulting engagement. The two layers rarely touch the same artifact.
Frequently asked questions
Is Pure Monograph competitive with IQVIA?
Only at the narrow edge where IQVIA sells regulatory authoring or CMC consulting hours. The bulk of IQVIA's business is clinical operations and data at enterprise scale.
What is IQVIA, in one line?
IQVIA (NYSE: IQV) is the publicly traded CRO formed from the IMS Health and Quintiles merger, offering clinical trials, real-world evidence, and commercial analytics at enterprise scale.
When would I use one versus the other?
Use IQVIA when you need to outsource a full trial program or run global commercial analytics. Use Pure Monograph when you need CTD, tech transfer, or CMC drafts and intelligence without a consulting retainer.
Do you replace CRO services?
No. The platform does not conduct trials, manage sites, or sign clinical agreements. It produces drafts and intelligence that sponsors or CROs use as inputs.